London Market Monitor – 31 August 2022
Our August review of the markets and Solvency II discount rates.
Providers that are interested in participating in CMMI’s recently announced Enhancing Oncology Model (EOM) will have to take on financial accountability for certain chemotherapy care for Medicare fee-for-service (FFS) patients. EOM builds on CMMI’s recently completed Oncology Care Model, with the aim of generating savings for the Medicare FFS program while enhancing the care provided to oncology patients. This article highlights key components and considerations of the new model, including changes to cancer types, risk arrangements, novel therapy adjustments, and other notable updates.
Enhancing Oncology Model (EOM): OCM “2.0”
This article highlights considerations for providers interested in voluntary enhanced oncology model, which builds on concepts of a recently completed CMMI model designed to transform oncology care while reducing spending under Medicare fee-for-service.